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Summary More accurate criteria are required for the selection of patients with node-negative breast cancer
for systemic adjuvant therapy. Expression of epidermal growth factor receptor (EGFr) has been shown
previously to be inversely related to oestrogen receptor (ER) in patients with operable breast cancer and to be
associated with a poorer prognosis. Analysis of EGFr and ER was performed on tumour samples from 231
patients with operable breast cancer followed for up to 6 years after surgery. The median duration of
follow-up in patients still alive at the time of analysis was 45 months. Thirty-five percent of patients (82) had
tumours with greater than 10 fmol mg-, I25-EGF binding (EGFr +) and 47% (109) and cystolic ER
concentrations >5 fmol mg-' (ER +), with a marked inverse relationship between EGFr and ER
(P<0.00001). In a univariate analysis EGFr was second only to axillary node status as a prognostic marker
for all patients both in terms of relapse-free and overall survival (P<0.001, log rank). For patients with
histologically negative axillary nodes EGFr was superior to ER in predicting relapse and survival (P<0.01
and P<0.005 respectively compared to P< 0.1 and P<0.1, log rank). In a multivariate (Cox model) analysis
only EGFr, out of EGFr, ER, size and grade, was predictive for either relapse-free or overall survival for
patients with node-negative disease (P = 0.05 and P = 0.026 respectively). EGFr has been shown to be a
marker of poor prognosis for patients with node-negative breast cancer. Since patients with EGFr + tumours
are unlikely to respond to hormone therapy it may be possible to select them for trials of systemic adjuvant
chemotherapy.
The histological status of the axillary lymph nodes, spec-
ifically the absolute number of nodes involved, remains the
most potent prognostic marker for patients with operable
breast cancer (Valagussa et al., 1978; Fisher et al., 1983).
Tumour recurrence and death due to breast cancer, however,
affects a significant proportion of patients with node-negative
disease (Fisher et al., 1989c). Recurrence rates of up to 43%
and mortality at 10 years of 32% have been reported (Fisher
et al., 1989b), suggesting a need for effective adjuvant sys-
temic therapy for selected patients in this supposedly good
prognostic subgroup.
It is now recognised that there is a need for a marker (or
markers) capable of discriminating patients with axillary
node-negative disease at high risk of recurrence and death.
Tumour oestrogen receptor (ER) content has been proposed
but there is disagreement about its value (Cooke et al., 1979;
Fisher et al., 1988). This has been supported by the long term
results of large trials evaluating the use of adjuvant tamox-
ifen for patients with operable breast cancer in which a
beneficial effect is shown also in patients with ER negative
tumours (Nolvadex Adjuvant Trial Organisation [NATO],
1988). Although recent trials of systemic adjuvant chemo-
therapy in patients with axillary node-negative disease and
ER negative tumours have shown small but significant
benefits in terms of recurrence-free survival, there was no
effect on overall survival (Fisher et al., 1989b; Mansour et al.,
1989; Ludwig breast cancer study group, 1989) but this may
reflect a relatively short follow-up. In one small trial there
was a benefit in terms of overall survival (Bonadonna &
Valagussa, 1987).
There have been several reports describing the presence of
specific, high affinity receptors for epidermal growth factor
(EGFr) on membranes prepared from primary human breast
carcinoma (Sainsbury et al., 1985; Perez et al., 1984). These
studies showed a marked inverse relationship between expres-
sion of EGFr and ER. Tumours which overexpressed EGFr
were associated with a poor overall prognosis (Sainsbury et
al., 1987; Rios et al., 1988) but short follow-up precluded
close examination of patient subgroups in particular node-
negative patients. Continued prospective patient follow-up
and increased patient numbers now allows examination of
the prognostic value of EGFr, particularly in node-negative
patients.
Patients and methods
Two hundred and thirty-one consecutive patients with opera-
table breast cancer and without biochemical or radiological
evidence ofdistant metastases were treated by simple mastec-
tomy (n = 181) or wide local excision and post-operative
radiotherapy by external beam and iridium wire implants
(n = 50). Level I axillary nodes (behind pectoralis major)
were sampled if palpable at surgery (n = 129, 56%). An
average of four nodes were sampled and for those with
positive nodes an average of three contained metastatic
tumour (range 1-8). In patients treated by mastectomy
adjuvant radiotherapy was given to the ipsilateral axilla if the
nodes were involved. No patient received adjuvant
chemotherapy in this study. Forty patients towards the end
of the study received adjuvant tamoxifen (20 mg daily) fol-
lowing the early results of the NATO study.
The resection specimens were taken immediately to the
Department of Pathology on ice. Maximum tumour diameter
was recorded and tumour blocks removed for histopath-
ology. Tumour specimens adjacent to the block for histology
were stored at - 20°C in a sucrose/glycerol medium (Craw-
ford et al., 1984) prior to receptor analysis. EGFr was deter-
mined using an I'25-labelled EGF radioreceptor assay with a
cut-off value of 10 fmol mg-' protein and ER by the dextran
charcoal method with a 5 fmol mg-' cytosol protein cut-off
as previously described (Nicholson et al., 1988b). Histological
examination of haematoxylin and eosin stained, formalin
fixed, paraffin embedded sections was performed and ductal
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carcinomas graded according to the modified Bloom and
Richardson method (Elston et al., 1982).
Follow-up was conducted every 3 months for the first 18
months, 6 monthly until 3 years and annually thereafter until
recurrence had been confirmed radiologically, cytologically or
histologically. Follow-up thereafter was every 3 months or
less until death. Patients with confirmed recurrent disease
were treated according to standard protocols in an advanced
medical oncoloy clinic (ALH). Patients with predominantly
soft tissue or skeletal disease were treated by endocrine
manipulation (tamoxifen ifpostmenopausal or oophorectomy
+ tamoxifen ifpremenopausal). Patients with visceral disease
and those who had failed first and second line endocrine
therapy were treated with chemotherapy - usually single
agent with either mitoxantrone or adriamycin. Patients with
isolated soft tissue relapse (axilla or mastectomy flap) usually
received radiotherapy in addition to endocrine manipulation.
Statistics
Analysis of patient and tumour characteristics within sub-
groups was performed using Chi-square contingency tables.
Survival data was analysed using the log rank method (Peto
et al., 1977) and the Cox proportional hazards regression
model (Cox, 1972).
Results
Relationship ofEGFr to other prognostic indicators
Of 231 patients, 213 (92%) had ductal carcinomas. Eight-
four patients (36%) were under 50 years of age and 147
(64%) were over 50. Eighty-two patients (35%) had tumours
with levels of EGFr> 10 fmol mg-' protein (EGFr positive)
and 109 patients (47%) had tumours with a cytosolic ER
content >5fmolmg-' (ER positive). There was a marked
inverse relationship between EGFr and ER (P<0.00001,
Table I).
In the 213 patients with ductal carcinomas there was a
significant association between increasing tumour grade and
expression of EGFr (P<0.025, Table II). There was no
relationship between EGFr and axillary node status (Table
III) or tumour size (Table IV).
Relationship ofEGFr to time to relapse and overall survival
After a median follow-up of 45 months for patients still alive
at the time of analysis, 125 patients (54%) have recurred and
Table I Relationship of tumour ER and EGFr expression in 231
patients with operable breast cancer
EGFr
_ ~~+
- 55 67 122 (53%)
ER
+ 94 15 109 (47%)
149 82 231
(65%) (35%)
X' = 40.808, dof = l, P<0.00001.
Table II Relationship between tumour grade and EGFr expression
in the 213 patients with ductal carcinomas
EGFr
- + % EGFr positive
Bloom & I 23 4 27 15 BloomR & II 49 24 73 33
Richardson III 63 50 113 44
135 78 213 37
X2= 8.805, dof= 2, P<0.025.
Table III Relationship between EGFr and axillary node status
according to clinical or histopathological assessment
A Clinical
EGFr
_+
Node 105 47 152
+ 44 35 79
149 82 231
x2=3.5, P0.06
B Histological
EGFr
_+
- 30 20 50
Node
+ 44 35 79
74 55 129
NS
(A) Histopathological; (B) assessment.
Table IV Relationship between EGFr and tumour size
EGFr
- + % EGFr positive
T, 36 17 53 32
Size T2 96 54 150 NS 36
T3 17 11 28 39
149 82 231 35
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Figure 1 Survival of patients with operable breast cancer strat-
ified by tumour EGFr expression; a, relapse-free, b, overall sur-
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there have been 80 breast cancer related deaths (35%). Fifty-
five patients out of 82 with EGFr positive tumours have
recurred compared with 70/149 with EGFr negative tumours
(P<0.001, log rank, Figure la). Forty-one patients out of 82
with EGFr positive tumours have died compared with 39/149
with EGFr negative tumours (P<0.001, log rank Figure Ib).
In a univariate analysis of prognostic factors in all 231
patients EGFr was second only to axillary node status
(clinical assessment) considering all patients (Table Va) or
those with histologically confirmed axillary node status
(Table Vb).
The effect of EGFr overexpression in specific patient
subgroups is shown in Table Vc. In the 50 patients with
histologically examined and negative axillary nodes EGFr
expression was associated with a significant reduction in
recurrence-free and overal survival (P<0.01 and <0.005
respectively - Figure 2a and b). Similarly in patients with
lower grade tumours (Grades I and II) there was a reduction
in recurrence-free and overall survival for those with EGFr
positive tumours (Figures 3a and b).
For patients with ER negative tumours co-expression of
EGFr reduced survival (Figure 4a). There was a similar trend
for patients whose tumours contained both EGFr and ER
(Figure 4b) but this did not reach statistical significance.
None of the factors analysed were of significance for patients
with positive nodes, although median relapse-free and overall
survival were approximately 10 months greater for patients
with node positive, EGFr negative tumours compared to
node positive, EGFr positive tumours by a univariate (log
rank) analysis.
Multivariate analysis ofsurvival data
A multivariate analysis was performed using a stepwise
regression (Cox) model. Five factors were assessed in this
analysis: axillary node status, tumour grade, tumour size
(analysed as a continuous variable only), EGFr and ER. This
allowed, therefore, analysis of only the 213 patients (92%)
with ductal carcinomas. The results are summarised in Table
VI. In the first analysis all the factors were assessed in all 213
patients (Table VIa). Clinical axillary node status was either
positive (sampled and histologically positive) or not positive
(sampled and histologically negative or unsampled). EGFr
was the only significant variable for recurrence-free survival
but just failed to reach significance for overall survival
(P = 0.059). Tumour size showed a trend only in terms of
recurrence-free survival. Neither ER nor tumour grade were
Table V Univariate analysis of survival data (log rank)
A Factor Disease-free Overall survival
Axillary nodes P<0.005 P<0.001
EGFr P<0.001 P<0.001
ER P<0.01 P<0.01
Tumour grade NS P<0.025
Size NS P<0.1
B Disease-free Overall survival
Axillary nodes P<0.005 P<0.001
EGFr P<0.01 P<0.01
ER NS P<0.1
Tumour grade NS NS
Size NS NS
C Disease-free Overall survival
Axillary node
negative P<0.01 P<0.005
Bloom &
Richardson
Grade I P<0.01 P<0.005
Grade II P<0.005 P<0.001
ER + P<0.05 P<0.1
ER- P<0.1 P<0.05
A: Effect of prognostic factors on survival of 231 patients; B:
Axillary node status known; C: Effect of overexpression of EGFr on
survival of patient subgroups.
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Figure 2 Survival of patients with histologically negative axillary
nodes stratified by tumour EGFr expression; a, relapse-free, b,
overall survival.
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Table VI Multivariate analysis (Cox model)
recurrence-free and overall survival of 213/231 pati
carcinomas
A 213 patients with ductal carcinoma
Covariate Recurrence Death
Lymph node P0.124 P0.
EGFr P0.031 P0.
ER NS NS
Bloom & Richardson NS P0.
Size P 0.055 NS
B 121 patients with ductal carcinomas and histol
status
Covariate Recurrence Death
Lymph node P0.027 P0.
EGFr P 0.053 P0
ER NS NS
Bloom & Richardson NS NS
Size P0.116 NS
C 49 patients with ductal carcinomas and histolo
axillary nodes
Covariate Recurrence Death
EGFr P0.05 P0.
ER NS NS
Bloom & Richardson NS NS
Size P0.01 NS
A: All patients (n = 213); B: Patients with histolot
node status (n = 121); C: Patients with histologicall3
(n = 49).
significant variables. In terms of overall surviv
node status was significant.
In the second analysis (Table VIb), 121 pat
tologically confirmed nodal status were ass(
results were similar to the first analysis with
status emerging as the most powerful prognos
both recurrence-free and overall survival (P = 0.027 and
P = 0.002 respectively). EGFr just failed to reach significance
in this analysis (P = 0.053 and P = 0.072 respectively).
Neither ER, tumour grade nor size were significant factors.
In the third analysis (Table VIc) only patients with axillary
node-negative (histologically confirmed), ductal carcinomas
(n = 49) were assessed. Both EGFr and tumour size were
significant factors for recurrence-free survival but only EGFr
was significant for overall survival.
Discussion
b 72 This study has emphasised the value of EGFr in selecting a
poor prognosis group within a population of patients with
46 operable breast cancer. The findings in the node negative
group are potentially of greater importance. The study, how-
ever, was conducted between 1983 and 1987 before the
worldwide results of adjuvant therapy were collated. During
this period it was the policy of many British surgeons to
94) perform only selective node sampling whereas now most
authorities would consider node sampling essential. In this
paper we have emphasised the analyses where node status
15) was histologically confirmed in order not to overstate the
extent of the findings.
There can be little doubt that patients with involved axil-
lary lymph nodes require adjuvant therapy but debate con-
tinues as to the optimum. Systemic adjuvant chemotherapy
almost certainly confers a survival advantage in premeno-
pausal patients (Fisher et al., 1986; Bonadonna et al., 1985)
but the mechanism of action has been questioned (Pad-
manabhan et al., 1986). In the postmenopausal node-positive
patient, tamoxifen therapy for 2 or more years significantly 41 improves survival (Nolvadex Adjuvant Trial Organisation,
1988; Breast Cancer Trials Committee; Scottish Cancer Trials
irs stratified by Office (MRC), 1987) regardless of ER status. There is in-
rs stratified by creasing evidence that some node-negative patients should
also receive adjuvant therapy but the criteria for selection are
not clear. A recent trial of adjuvant tamoxifen in node-
negative patients with ER positive tumours (Fisher et al.,
t of data for 1989a) showed an advantage in the treated group in terms of
disease-free but not overall survival.
These studies suggest that, although ER may be a useful
prognostic marker overall (Cooke et al., 1979) and in predict-
ing response to endocrine therapy at relapse (Leake et al.,
.0005 1981), it may not be so useful in assigning different patient
.059 subgroups to the currently available adjuvant therapies.
Thymidine labelling has been used as a prognostic marker
.142 in node-negative disease (Silvestrini et al., 1985) but the
technique is complex and time consuming and, therefore,
fogical node probably not applicable to routine clinical practice. A recent
study (Clark et al., 1989) showed that flow cytometry may
offer a practical alternative. In this study disease-free survival
.002 for patients with node-negative breast cancer was signifi-
.072 cantly worse if their tumours were either aneuploid or diploid
with a high S-phase fraction.
Expression of the c-erbB-2 oncoprotein, which can be
measured using immunohistochemical staining of formalin
gically negative fixed, paraffin embedded sections, has recently been evaluated
as a prognostic marker in breast cancer with promising
results (Wright et al., 1989), but its prognostic power may be
.026 greatest in node-positive patients (Slamon et al., 1987) from
whom few clinicians would now withhold adjuvant therapy.
Overexpression of EGFr has been shown previously to be
a marker of early relapse and death in patients with operable
gically confirmed breast cancer (Sainsbury et al., 1987; Rios et al., 1988).
negative nodes Overexpression ofEGFr inbreast tumours of elderly patients
treated with primary endocrine therapy was associated with
rapid disease progression and poor response rates (Nicholson
tal only lymph et al., 1988a) as in patients with recurrent breast cancer after
surgical treatment (Nicholson et al., 1989). For these reasons
Lients with his- we felt it was appropriate to include the small number of
essed and the patients accrued at the end of the study who received
axillary nodal adjuvant tamoxifen, since the survival of at least those with
;tic marker for EGFr positive tumours was unlikely to be influenced.150 S. NICHOLSON et at.
This study has demonstrated that overexpression of EGFr
in tumours of patients with operable breast cancer is asso-
ciated with a poor overall prognosis and that EGFr status is
second only to axillary lymph node status in its prognostic
power. In subgroups which would otherwise have been con-
sidered to have a good prognosis (axillary node-negative and
low tumour grade) overexpression of EGFr led to a
significant reduction in both relapse-free and overall survival.
Similarly, patients whose tumours coexpressed EGFr and ER
had survival patterns similar to those expressing EGFr alone,
suggesting that overexpression of EGFr conferred a growth
potential on a tumour which obviated its requirement for
oestrogen. Although the node negative (histologically
confirmed) groups was relatively small the magnitude of the
differences in this group between those with EGFr negative
and positive tumours was great. In a multivariate analysis
when clinical node status was assessed the effect of EGFr
expression in the node negative group was enhanced
(P = 0.01 for relapse-free and overall survival) suggesting
that these differences are indeed of practical importance.
These results, together with those which have shown a
failure of response to endocrine therapy associated with
overexpression, suggest that EGFr may be a clinically useful
prognostic marker in patients with axillary node-negative
breast cancer capable of identifying a poor prognosis sub-
group which may benefit from systemic adjuvant chemo-
therapy.
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